Iambic
San Diego
About Iambic
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures. The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $303.0M
- Last round: Series Unknown (Nov 2025)
- Website: iambic.ai
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Machine Learning, Software, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/iambic-51598 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.